{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:56:17Z","timestamp":1790553377550,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding and National Cancer Center Climbing Fund","award":["No. NCC202414002"],"award-info":[{"award-number":["No. NCC202414002"]}]},{"name":"The Science Cand Technology Department Basic Research Project of Shanxi","award":["No. 202203021221284"],"award-info":[{"award-number":["No. 202203021221284"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56400-0","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:37:56Z","timestamp":1782797876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Down-staging depth score could be a survival predictor for locally advanced breast cancer patients after neoadjuvant chemotherapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Miaoli","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"2","key":"56400_CR1","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115\u2013132 (2016).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"56400_CR2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7093","volume":"23","author":"C Boman","year":"2025","unstructured":"Boman, C. et al. Prognosis after pathologic complete response to neoadjuvant therapy in early-stage breast cancer: A population-based study. J. Natl. Compr. Canc. Netw. 23(4), e247093 (2025).","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"56400_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5644\/ama2006-124.328","volume":"50","author":"E Provenzano","year":"2021","unstructured":"Provenzano, E. Neoadjuvant chemotherapy for breast cancer: Moving beyond pathological complete response in the molecular age. Acta Med. Acad. 50(1), 88\u2013109 (2021).","journal-title":"Acta Med. Acad."},{"issue":"10","key":"56400_CR4","first-page":"103","volume":"25","author":"A Pennisi","year":"2016","unstructured":"Pennisi, A. et al. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer (Auckl). 25(10), 103\u2013106 (2016).","journal-title":"Breast Cancer (Auckl)."},{"issue":"2","key":"56400_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00432-019-03083-y","volume":"146","author":"N LeVasseur","year":"2020","unstructured":"LeVasseur, N. et al. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. J. Cancer Res. Clin. Oncol. 146(2), 529\u2013536 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"56400_CR6","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18(3), e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"issue":"3","key":"56400_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.21147\/j.issn.1000-9604.2018.03.09","volume":"30","author":"N Li","year":"2018","unstructured":"Li, N. et al. Downstaging depth score to predict outcomes in locally advanced rectal cancer achieving ypI stage after neoadjuvant chemoradiotherapy versus de novo stage pI cohort: A propensity score-matched analysis. Chin J Cancer Res. 30(3), 373\u2013381 (2018).","journal-title":"Chin J Cancer Res."},{"issue":"4","key":"56400_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.21147\/j.issn.1000-9604.2021.04.02","volume":"33","author":"N Li","year":"2021","unstructured":"Li, N. et al. Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy. Chin J Cancer Res. 33(4), 447\u2013456 (2021).","journal-title":"Chin J Cancer Res."},{"issue":"8","key":"56400_CR9","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher, B. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16(8), 2672\u20132685 (1998).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"56400_CR10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi, P. et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 26(5), 778\u2013785 (2008).","journal-title":"J Clin Oncol."},{"issue":"12","key":"56400_CR11","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch, M. et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol. 28(12), 2024\u20132031 (2010).","journal-title":"J Clin Oncol."},{"issue":"7","key":"56400_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 15(7), 747\u2013756 (2014).","journal-title":"Lancet Oncol."},{"issue":"15","key":"56400_CR13","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz, G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30(15), 1796\u20131804 (2012).","journal-title":"J Clin Oncol."},{"issue":"11","key":"56400_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.735670","volume":"24","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Miller-payne grading and 70-gene signature are associated with prognosis of hormone receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer after neoadjuvant chemotherapy. Front Oncol. 24(11), 735670 (2021).","journal-title":"Front Oncol."},{"issue":"8","key":"56400_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jama.2024.23560","volume":"333","author":"L Chen","year":"2025","unstructured":"Chen, L. et al. Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: The camrelief randomized clinical trial. JAMA 333(8), 673\u2013681 (2025).","journal-title":"JAMA"},{"issue":"9957","key":"56400_CR16","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/S0140-6736(14)62240-6","volume":"384","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2014","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Postmastectomy radiotherapy in patients with breast cancer - Authors\u2019 reply. Lancet 384(9957), 1846\u20131847 (2014).","journal-title":"Lancet"},{"key":"56400_CR17","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-45654-1","volume":"36","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Patients achieved pCR during neoadjuvant chemotherapy had better outcome than adjuvant chemotherapy setting in breast cancer: A comparative study. Cancer Treat. Res. Commun. 36, 100719 (2023).","journal-title":"Cancer Treat. Res. Commun."},{"issue":"1","key":"56400_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4132\/jptm.2016.10.05","volume":"51","author":"M Choi","year":"2017","unstructured":"Choi, M. et al. Evaluation of pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy: Experience in a single institution over a 10-year period. J. Pathol. Transl. Med. 51(1), 69\u201378 (2017).","journal-title":"J. Pathol. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56400-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:13:36Z","timestamp":1790550816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56400-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56400"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56400-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Shanxi Province Cancer Hospital. Given the retrospective nature and minimal risk to participants, the committee waived the requirement for individual written informed consent. All procedures were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval and Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent for publication is not required as this study does not contain any identifiable personal information or images of participants.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29977"}}